InvestorsHub Logo
Followers 12
Posts 3795
Boards Moderated 0
Alias Born 04/30/2004

Re: None

Wednesday, 12/22/2021 3:03:32 PM

Wednesday, December 22, 2021 3:03:32 PM

Post# of 1450
Lineage Cell Therapeutics (LCTX) Received its Third Buy in a Row

Source: TipRanks
After H.C. Wainwright and Maxim Group gave Lineage Cell Therapeutics (NYSE MKT: LCTX) a Buy rating last month, the company received another Buy, this time from Noble Financial. Analyst Robert LeBoyer reiterated a Buy rating on Lineage Cell Therapeutics today and set a price target of $8.00. The company's shares closed last Monday at $2.57. According to TipRanks.com, LeBoyer is a 5-star analyst with an average return of 29.0% and a 36.5% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Onconova Therapeutics, PDS Biotechnology, and Cocrystal Pharma.
https://www.tipranks.com/news/blurbs/lineage-cell-therapeutics-lctx-received-its-third-buy-in-a-row-2?utm_source=advfn.com&utm_medium=referral
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LCTX News